Core Viewpoint - The China Securities Regulatory Commission has approved Hanx Biopharmaceuticals (Wuhan) Co., Ltd. to issue up to 21,069,700 overseas listed ordinary shares and convert 117,897,830 domestic unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Company Overview - Hanx Biopharmaceuticals is an innovative biotech company specializing in structural biology, translational medicine, and clinical development, with a focus on building an innovative pipeline since 2016 [1] - The company has developed a core product and nine other pipeline candidates, including three clinical-stage candidates for oncology (HX009, HX301, and HX044) and seven preclinical candidates targeting autoimmune and oncology markets [1] Shareholder Information - A total of 15 shareholders will convert their shares, with the largest shareholding being from Cai Zhang Biotechnology (Hangzhou) Co., Ltd., holding 55,300,000 shares [2] - Other notable shareholders include Hanx Biopharmaceuticals (HK) Limited with 17,793,640 shares and Beijing Longpan Biopharmaceutical Venture Capital Center with 12,860,470 shares [2] - The total number of shares being converted amounts to 117,897,830 [2]

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 38.26 RMB and a 2026 PE of 41X [4][9]. Core Insights - The company's core product, dust mite drops, is steadily growing, while the new product, artemisia annua drops, is rapidly gaining market share. The prick test solution product line is also expanding, and there are multiple advancements in the R&D pipeline [1][4]. - In the first three quarters of 2025, the company achieved a revenue of 0.85 billion RMB, representing a growth of 16.86%, and a net profit attributable to shareholders of 0.35 billion RMB, which is an increase of 26.67% [4][9]. - The company has effectively controlled costs, leading to profit growth that outpaces revenue growth, primarily due to a decrease in expense ratios and refined sales management [4][9]. Financial Summary - The company’s projected financials show a revenue increase from 848 million RMB in 2023 to 1.525 billion RMB in 2027, with a CAGR of approximately 18.9% [3][5]. - Net profit attributable to shareholders is expected to grow from 310 million RMB in 2023 to 595 million RMB in 2027, reflecting a CAGR of about 21.7% [3][5]. - The earnings per share (EPS) forecast is adjusted to 0.77 RMB for 2025, 0.93 RMB for 2026, and 1.14 RMB for 2027 [4][9]. Product Performance - By product, dust mite revenue reached 0.79 billion RMB (+13.38%), artemisia annua revenue was 44.76 million RMB (+117.58%), and prick test solution revenue was 11.05 million RMB (+94.10%) in the first three quarters of 2025 [4][9]. - In Q3 2025 alone, the company reported a revenue of 0.37 billion RMB (+22.64%) and a net profit of 0.17 billion RMB (+36.44%) [4][9]. R&D Pipeline - The company is advancing its allergen product development, with several products in various stages of clinical trials, including the artemisia annua pollen sublingual drops and dermatitis diagnostic patches [4][9]. - Current R&D products include the house dust mite membrane agent in Phase I, and two dermatitis diagnostic patches in Phase I and II clinical trials [4][9].

Core Insights - The report maintains a neutral rating for the pharmaceutical and biotechnology industry, indicating that while there are pressures on performance, there are also opportunities in specific segments that are experiencing growth [5][30]. Market Performance Review - In the first ten months of 2025, the SW pharmaceutical and biotechnology index increased by 21.10%, outperforming the CSI 300 index by approximately 2.26 percentage points, ranking 12th among all Shenwan primary industries [14][19]. - Most sub-sectors within the industry recorded positive returns, with the medical research outsourcing and chemical preparation sectors leading with increases of 60.54% and 40.80%, respectively. Conversely, the blood products and vaccine sectors saw declines of 7.89% and 1.60% [15][19]. - As of October 31, 2025, the overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 53.97 times, which is 4.06 times higher than the CSI 300 index, indicating an increase in industry valuation [19][20]. Policy Outlook for H1 2026 - The 11th batch of national drug centralized procurement is expected to be fully implemented in the first half of 2026, involving 55 varieties and 272 companies, with a selection rate of 57% [30][31]. - The procurement results show a high match between selected brands and clinical needs, with strong supply capabilities from mainstream companies [30]. Sub-sector Highlights Innovative Drugs - Continuous policy optimization supports the development of innovative drugs, with a comprehensive approach to enhance pricing management, insurance coverage, and investment [38]. - The industry is gradually moving away from homogeneous competition, with a significant increase in the proportion of First-in-Class new drug development, which rose by 23 percentage points to 35% since 2020 [38][39]. - Domestic innovative drugs are gaining international recognition, with outbound licensing transactions reaching $66 billion in the first half of 2025, reflecting a growing global presence [41][44]. Medical Devices - The aging population in China is projected to exceed 400 million by 2035, driving demand for medical services and supporting stable growth in the medical device market [50]. - The global medical device market is expected to grow at a compound annual growth rate (CAGR) of 5.7%, reaching $869.7 billion by 2030 [52]. - China's medical device market is rapidly expanding, with projected revenues of 187.5 billion yuan by 2025, indicating significant growth potential [53]. Aesthetic Medicine - The domestic aesthetic medicine market is expected to steadily increase, supported by various policies aimed at promoting healthy industry development and improving market concentration [39]. Synthetic Biology - The market size for synthetic biology is anticipated to approach $40 billion by 2027, driven by multiple factors including technological advancements and increased investment [39].

Core Viewpoint - The company emphasizes that its business development is a long-term endeavor that requires addressing various challenges and difficulties proactively [2] Group 1: Business Development - Since its listing on the Growth Enterprise Market, the company has steadily developed its business, transitioning from a single product to a multi-product sales model [2] - Revenue and net assets have continued to grow, indicating a positive financial trajectory [2] Group 2: Strategic Focus - The company remains committed to innovation and hard work, aiming to strengthen its strategic direction through four key areas: research and development, market expansion, strategic partnerships, and ecosystem development [2] - There is a focus on embracing change and driving transformation by optimizing research strategies, enhancing research efficiency, and strengthening the layout of cutting-edge technologies [2] Group 3: Long-term Value Creation - The company aims to enhance its innovative vitality and accelerate the realization of the value of its innovative achievements, thereby achieving long-term growth in company value [2]

Core Viewpoint - The short-term stock price fluctuations of the company are influenced by various market factors, while the long-term stock price is more dependent on the company's intrinsic value [1] Group 1: Company Operations - The company is currently operating normally and is making efforts to achieve its operational goals for 2025 [1] - The team is intensifying efforts to meet the 2025 operational plan [1] Group 2: Market Activities - The company's plan for issuing and listing on the Hong Kong stock market is progressing as scheduled [1]

Investment Rating - The report suggests a cautious investment outlook for the pharmaceutical and biotechnology sector, highlighting a slow recovery influenced by various factors such as price reductions from centralized procurement and healthcare cost control measures [2][12]. Core Insights - The overall performance of the pharmaceutical and biotechnology sector is under pressure, with a slight improvement in Q3 2025. The 452 listed companies in this sector reported total revenue of CNY 1.85 trillion, a year-on-year decrease of 1.9%, and a net profit of CNY 140.6 billion, down 4.8% year-on-year [2][12]. - The sector's overall gross margin stands at 30.87%, down 0.66 percentage points year-on-year, while the net margin is at 8.00%, down 0.28 percentage points year-on-year, indicating historically low profitability [2][29]. - There is significant performance differentiation among sub-sectors, with innovative drugs showing strong growth. The top five sub-sectors by revenue growth in Q3 2025 are innovative drugs (+23.34%), CXO (+12.36%), other biological products (+8.15%), upstream reagents (+6.11%), and pharmacies (+0.74%) [2][35]. Summary by Sections 1. Industry Overview - The pharmaceutical manufacturing industry achieved revenue of CNY 1.82 trillion in the first three quarters of 2025, a year-on-year decline of 2.00%, with total profits of CNY 253.48 billion, down 0.70% year-on-year [11][12]. - The industry's revenue and profit growth rates are significantly below the national industrial growth rate of 6.20%, indicating ongoing pressure [11][12]. 2. Sub-sector Performance - The innovative drug sector continues to perform well, with a revenue increase of 23.34% and a net profit growth of 94.98% in Q3 2025 [2][35]. - The CXO sector also shows strong performance, with a revenue increase of 12.36% and a net profit increase of 55.90% [2][93]. - Other sub-sectors such as upstream reagents and pharmacies also reported positive growth, while traditional sectors like raw materials and vaccines faced significant declines [2][35][137]. 3. Company Recommendations - The report recommends focusing on investment opportunities in innovative drug chains, medical devices, healthcare services, second-class vaccines, chain pharmacies, traditional Chinese medicine, and raw materials [2]. 4. Market Trends - As of November 6, 2025, the pharmaceutical and biotechnology sector has seen an 18.61% increase, underperforming compared to the CSI 300 index [36]. - The sector's valuation is at a historical median level, with a PE ratio of 30.13, indicating a potential for recovery as market conditions improve [41].

Core Insights - The company Beida Pharmaceutical has signed a strategic cooperation agreement with Hangzhou Ruipu Morning Technology Co., Ltd. to invest in the field of stem cell differentiation technology towards pancreatic cells [2] - The clinical research for RGB-5088, a pancreatic cell injection treatment for Type 1 diabetes developed by Ruipu Morning, is currently in progress [2] - The company will monitor developments in other areas and will disclose any significant collaborations in a timely manner [2]

Core Viewpoint - Beida Pharmaceutical has established a robust organizational structure with over 1,800 employees, focusing on market expansion and resource efficiency to enhance shareholder value [2] Group 1 - As of June 30, 2025, the company will have more than 1,800 employees, including nearly 300 in the R&D team and 1,100 in the commercialization team [2] - The company has developed a comprehensive marketing network that covers over 30 provinces in China and has established long-term partnerships with several leading distributors, effectively reaching over 3,000 hospitals [2] - All employees are actively implementing the company's operational plans, strengthening product market strategies, and concentrating resources on key development pipelines to achieve breakthrough growth [2]

Group 1 - The core viewpoint of the article highlights that Beida Pharmaceutical values investor interaction and communication, utilizing multiple channels for engagement [2] - The company emphasizes the importance of holding annual performance briefings within fifteen trading days after the annual report disclosure, as encouraged by exchange rules [2] - Beida Pharmaceutical maintains communication through various platforms, including interactive platforms, investor hotlines, WeChat public accounts, performance briefings, and broker strategy meetings [2]

Investment Rating - The report suggests a cautious investment outlook for the pharmaceutical and biotechnology sector, highlighting a slow recovery due to various factors such as price reductions from centralized procurement and healthcare cost control measures [2][12]. Core Insights - The overall performance of the pharmaceutical and biotechnology sector is under pressure, with a slight improvement in Q3 2025. The 452 listed companies in this sector reported a total revenue of CNY 1.85 trillion, a year-on-year decrease of 1.9%, and a net profit of CNY 140.6 billion, down 4.8% year-on-year [2][12]. - The sector's overall gross margin is at 30.87%, down 0.66 percentage points year-on-year, while the net margin is at 8.00%, down 0.28 percentage points year-on-year, indicating historically low profitability [2][29]. - There is significant performance differentiation among sub-sectors, with innovative drugs showing strong growth. The top five sub-sectors by revenue growth are innovative drugs (+23.34%), CXO (+12.36%), other biological products (+8.15%), upstream reagents (+6.11%), and pharmacies (+0.74%) [2][35]. Summary by Sections 1. Overall Industry Situation - The pharmaceutical manufacturing industry achieved a revenue of CNY 1.82 trillion in the first three quarters of 2025, a year-on-year decline of 2.00%, with total profits of CNY 253.48 billion, down 0.70% year-on-year [11][12]. - The industry's revenue and profit growth rates are significantly below the national industrial growth rate of 6.20% [11]. 2. Sub-sector Performance - The innovative drug sector continues to perform well, with a revenue increase of 23.34% and a net profit growth of 94.98% in Q3 2025 [2][35]. - The CXO sector also showed strong performance, with a revenue increase of 12.36% and a net profit increase of 55.90% [2][93]. - Other sub-sectors such as upstream reagents and pharmacies also reported positive growth, while traditional sectors like raw materials and vaccines faced significant declines [2][35][137]. 3. Company Recommendations - The report recommends focusing on investment opportunities in innovative drug chains, medical devices, healthcare services, second-class vaccines, chain pharmacies, traditional Chinese medicine, and raw materials [2]. 4. Market Trends - As of November 6, 2025, the pharmaceutical and biotechnology sector has seen an 18.61% increase, underperforming compared to the CSI 300 index [36]. - The sector's valuation is at a historical median level, with a PE ratio of 30.13, indicating a recovery from previous declines [41].